Jiangsu Bioperfectus Technology Co., Ltd. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2010

Location

Taizhou Jiangsu China

Primary Industry

Biotechnology

About

Based in Taizhou, China and established in 2010, Jiangsu Bioperfectus Technology Co., Ltd. is a nucleic acid and protein detection product developer. It has a branch in Shanghai. It also has acquired High-Tech Enterprise Certificate. In March 2017, Jiangsu Bioperfectus Technology Co., Ltd. closed a venture funding from new investors Lyfe Capital and Tianyi Investment Group. In November 2019, It raised RMB 685.79 million in an IPO, selling 14.66 million share at RMB 46.78 per share on the Shanghai Stock Exchange. The company's products mainly include biological technology platforms such as fluorescent quantitative PCR, biochips, and enzyme chemistry. It has developed products such as infectious disease pathogen detection, female reproductive tract microecology detection, and tumor screening. The company generates revenue by developing molecular diagnostic technology and provides related products.

Current Investors

Tianyi Investment Group, LYFE Capital, CID Group

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Diagnostic, Medical & Imaging Laboratories, Healthcare IT

Website

www.bioperfectus.cn

Verticals

HealthTech

Company Stage

Mature

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.